Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Conba Pharmaceutical Co has a current ratio of 1.98. It generally indicates good short-term financial strength.
The historical rank and industry rank for Zhejiang Conba Pharmaceutical Co's Current Ratio or its related term are showing as below:
SHSE:600572'
s Current Ratio Range Over the Past 10 Years
Min: 1.09 Med: 1.64 Max: 2.15
Current: 1.98
During the past 13 years, Zhejiang Conba Pharmaceutical Co's highest Current Ratio was 2.15. The lowest was 1.09. And the median was 1.64.
SHSE:600572's Current Ratio is ranked worse than 50.35% of 999
companies
in the Drug Manufacturers industry
Industry Median: 2
vs SHSE:600572: 1.98
Zhejiang Conba Pharmaceutical Co (SHSE:600572) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Zhejiang Conba Pharmaceutical Co Current Ratio Related Terms
Zhejiang Conba Pharmaceutical Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co Current Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Conba Pharmaceutical Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a Current Ratio of 1.98 as of Mar. 2026. This is 21% above median its historical median of 1.64. Over the past decade, Zhejiang Conba Pharmaceutical Co's Current Ratio has ranged from 1.09 to 2.15. According to the industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #503 out of 999 companies in the Drug Manufacturers industry, placing it in the top 50.4%.
Is Zhejiang Conba Pharmaceutical Co's Current Ratio too high?
Zhejiang Conba Pharmaceutical Co's current Current Ratio of 1.98 is 21% above median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 2.15. The Drug Manufacturers industry median Current Ratio is 2.00. Zhejiang Conba Pharmaceutical Co's value of 1.98 is 1% below this industry median. Based on the distribution chart, Zhejiang Conba Pharmaceutical Co ranks #503 out of 999 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #503 out of 999 companies for Current Ratio. This places Zhejiang Conba Pharmaceutical Co in the lower half of its industry. The industry median Current Ratio is 2.00. Zhejiang Conba Pharmaceutical Co's value of 1.98 is 1% below this benchmark. Historically, Zhejiang Conba Pharmaceutical Co's own Current Ratio has ranged from 1.09 to 2.15 over the past decade. While the company's 10-year median is 1.64 vs. the industry median of 2.00, Zhejiang Conba Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Conba Pharmaceutical Co's current Current Ratio of 1.98 is 1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Conba Pharmaceutical Co's current Current Ratio is 1.98, which is 21% above median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.51, compared to a current price of ¥4.32 — trading 21.6% below its estimated fair value. The current Current Ratio is 1.98, which is 21% above median its 10-year median of 1.64 and 1% below the Drug Manufacturers industry median of 2.00. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current Current Ratio is 1.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.32 is trading 21.6% below its estimated GF Value™ of ¥5.51.
GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600572:
Current Ratio: 1.98 (21% above median its 10-year median of 1.64)
GF Value™: ¥5.51 vs. price of ¥4.32 (21.6% below fair value)
Industry Position: 1% below the Drug Manufacturers median (#503 of 999)
No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Conba Pharmaceutical Co Business Description
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
71GF Score
Get the complete analysis for SHSE:600572
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600572 has been successfully added to your 
